Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of approach to prostate cancer survivors

Ted A Skolarus, MD, MPH
Section Editors
Larissa Nekhlyudov, MD, MPH
Jerome P Richie, MD, FACS
Deputy Editor
Michael E Ross, MD


Prostate cancer is the second most common cancer in men worldwide and the most common non-cutaneous malignancy in men within the United States (US). Although it is the second leading cause of cancer-related death in men after lung cancer in the US, cancer-specific survival is excellent for most patients. Due to a generally older age at presentation, earlier detection, effective treatment, and a protracted clinical course for most men, prostate cancer survivors have a higher risk of death from non-cancer causes [1].

In the US alone, almost three million men are survivors of prostate cancer, comprising 43 percent of the total US male cancer survivor population [2]. It is estimated that by 2024, prostate cancer survivors will exceed four million in number, highlighting the importance of collaboration between primary care providers and cancer specialists so that these patients' unique needs can be met efficiently [2].

This topic will discuss the approach to prostate cancer survivors and is focused on patients seen in a coordinated care setting between their primary care and oncology providers or those exclusively cared for by their primary care providers. For purposes of this discussion, cancer survivors are characterized as men who have been diagnosed with prostate cancer and have completed all treatment for prostate cancer. The approach presented in this topic is consistent with guidelines from the American Cancer Society [3], the American Society of Clinical Oncology (ASCO) [4], and the National Comprehensive Cancer Network (NCCN) [5].

Further information on the diagnosis, staging, and treatment of prostate cancer is discussed separately. (See "Clinical presentation and diagnosis of prostate cancer" and "Initial staging and evaluation of men with newly diagnosed prostate cancer" and "Prostate cancer: Risk stratification and choice of initial treatment".)


Diagnosis and staging — Over 90 percent of patients present with local or locoregional disease due to the widespread use of prostate cancer screening (ie, use of prostate-specific antigen [PSA] or digital rectal examination [DRE]) [6]. In the remainder of patients, the diagnosis is typically suspected based on symptoms of advanced cancer (eg, urinary tract obstruction, hematuria, bone pain). Regardless of clinical suspicion, the diagnosis of prostate cancer requires histologic confirmation. (See "Clinical presentation and diagnosis of prostate cancer".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jan 8, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 2009; 57:24.
  2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64:252.
  3. Skolarus TA, Wolf AM, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014; 64:225.
  4. Resnick MJ, Lacchetti C, Bergman J, et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol 2015; 33:1078.
  5. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 4.2013) http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed on August 05, 2013).
  6. Surveillance, Epidemiology and End Results (SEER) program www.seer.cancer.gov (Accessed on April 17, 2013).
  7. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate cancer early detection. Version 2.2012. http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf (Accessed on April 17, 2013).
  8. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969.
  9. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 1. 2015. http://www.nccn.org/professionals/physician (Accessed on January 14, 2015).
  10. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer 2011; 117:2058.
  11. Klotz LH, Nam RK. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis. Can J Urol 2006; 13 Suppl 1:48.
  12. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347:781.
  13. Harlan SR, Cooperberg MR, Elkin E, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003; 170:1804.
  14. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer, Version 2.2013. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed on April 17, 2013).
  15. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012; 156:591.
  16. "Results Unproven, Robotic Surgery Wins Converts." New York Times online edition. http://www.nytimes.com/2010/02/14/health/14robot.html?hpw (Accessed on April 17, 2013).
  17. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol 2012; 103:8.
  18. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314.
  19. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013; 31:2029.
  20. Salonen AJ, Taari K, Ala-Opas M, et al. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012; 187:2074.
  21. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250.
  22. Gore JL, Kwan L, Lee SP, et al. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009; 101:888.
  23. Jacobs BL, Zhang Y, Skolarus TA, et al. Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol 2014; 65:162.
  24. Coelho RF, Chauhan S, Palmer KJ, et al. Robotic-assisted radical prostatectomy: a review of current outcomes. BJU Int 2009; 104:1428.
  25. Tsivian M, Mayes JM, Krupski TL, et al. Altered male physiologic function after surgery for prostate cancer: couple perspective. Int Braz J Urol 2009; 35:673.
  26. Sinfield P, Baker R, Agarwal S, Tarrant C. Patient-centred care: What are the experiences of prostate cancer patients and their partners? Patient Educ Couns 2008; 73:91.
  27. Wittmann D, Northouse L, Foley S, et al. The psychosocial aspects of sexual recovery after prostate cancer treatment. Int J Impot Res 2009; 21:99.
  28. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin 2010; 60:194.
  29. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24:4448.
  30. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27:92.
  31. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008; 54:816.
  32. Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008; 26:585.
  33. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306:2359.
  34. Michaelson MD, Cotter SE, Gargollo PC, et al. Management of complications of prostate cancer treatment. CA Cancer J Clin 2008; 58:196.
  35. Michigan Cancer Consortium Prostate Cancer Action Committee. Guidelines for Primary Care Management of Prostate Cancer Post-Treatment Sequelae. http://www.michigancancer.org/PDFs/MCCGuidelines-PrimaryCareMgtProstateCaPost-TxSequelae.pdf (Accessed on April 17, 2013).
  36. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205.
  37. Ferrer M, Suárez JF, Guedea F, et al. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72:421.
  38. Ficarra V, Novara G, Artibani W, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009; 55:1037.
  39. Wittmann D, He C, Coelho M, et al. Patient preoperative expectations of urinary, bowel, hormonal and sexual functioning do not match actual outcomes 1 year after radical prostatectomy. J Urol 2011; 186:494.
  40. Pardo Y, Guedea F, Aguiló F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol 2010; 28:4687.
  41. Miller DC, Wei JT, Dunn RL, et al. Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference. Urology 2006; 68:166.
  42. Braun K, Ahallal Y, Sjoberg DD, et al. Effect of repeated prostate biopsies on erectile function in men on active surveillance for prostate cancer. J Urol 2014; 191:744.
  43. Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009; 182:2664.
  44. Basal S, Wambi C, Acikel C, et al. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int 2013; 111:658.
  45. Müller A, Parker M, Waters BW, et al. Penile rehabilitation following radical prostatectomy: predicting success. J Sex Med 2009; 6:2806.
  46. Fenner A. Prostate cancer: postprostatectomy climacturia. Nat Rev Urol 2011; 8:473.
  47. Choi JM, Nelson CJ, Stasi J, Mulhall JP. Orgasm associated incontinence (climacturia) following radical pelvic surgery: rates of occurrence and predictors. J Urol 2007; 177:2223.
  48. Garcia FJ, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol 2010; 20:234.
  49. Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010; 105:37.
  50. Carlsson S, Nilsson AE, Johansson E, et al. Self-perceived penile shortening after radical prostatectomy. Int J Impot Res 2012; 24:179.
  51. Benson JS, Abern MR, Levine LA. Penile shortening after radical prostatectomy and Peyronie's surgery. Curr Urol Rep 2009; 10:468.
  52. Vasconcelos JS, Figueiredo RT, Nascimento FL, et al. The natural history of penile length after radical prostatectomy: a long-term prospective study. Urology 2012; 80:1293.
  53. Eylert MF, Bahl A, Persad R. Do we need to obtain consent for penile shortening as a complication of treatment for organ-confined prostate cancer? BJU Int 2012; 110:1491.
  54. Reese JB. Coping with sexual concerns after cancer. Curr Opin Oncol 2011; 23:313.
  55. Wassersug RJ, Oliffe JL. The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management. J Sex Med 2009; 6:989.
  56. Kaplan AL, Hu JC, Morgentaler A, et al. Testosterone Therapy in Men With Prostate Cancer. Eur Urol 2016; 69:894.
  57. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2014; 17:132.
  58. Kaplan AL, Lenis AT, Shah A, et al. Testosterone replacement therapy in men with prostate cancer: a time-varying analysis. J Sex Med 2015; 12:374.
  59. Kaplan AL, Trinh QD, Sun M, et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med 2014; 11:1063.
  60. Meza J, Weaver K, Martin S. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer. Am Fam Physician 2013; 88:Online.
  61. (http://www.auanet.org/about/testosterone-therapy.cfm) (Accessed on January 14, 2015).
  62. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159:507.
  63. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102:39.
  64. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009; 24 Suppl 2:S389.
  65. Keating NL, Liu PH, O'Malley AJ, et al. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014; 65:816.
  66. Elliott SP, Jarosek SL, Alanee SR, et al. Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture. Cancer 2011; 117:4557.
  67. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch Intern Med 2006; 166:465.
  68. Nieder AM, Porter MP, Soloway MS. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008; 180:2005.
  69. Bill-Axelson A, Garmo H, Holmberg L, et al. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol 2013; 64:920.
  70. Stone P, Hardy J, Huddart R, et al. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36:1134.
  71. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21:1653.
  72. Pirl WF, Greer JA, Goode M, Smith MR. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology 2008; 17:148.
  73. Korfage IJ, Essink-Bot ML, Janssens AC, et al. Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer 2006; 94:1093.
  74. Couper JW, Love AW, Dunai JV, et al. The psychological aftermath of prostate cancer treatment choices: a comparison of depression, anxiety and quality of life outcomes over the 12 months following diagnosis. Med J Aust 2009; 190:S86.
  75. Punnen S, Cowan JE, Dunn LB, et al. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int 2013; 112:E67.
  76. Nelson CJ, Weinberger MI, Balk E, et al. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist 2009; 14:891.
  77. Roth AJ, Kornblith AB, Batel-Copel L, et al. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 1998; 82:1904.
  78. Klotz LH. PSAdynia and other PSA-related syndromes: a new epidemic--a case history and taxonomy. Urology 1997; 50:831.
  79. Lofters A, Juffs HG, Pond GR, Tannock IF. "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol 2002; 168:2516.
  80. Carlsson S, Sandin F, Fall K, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer 2013; 49:1588.
  81. Harden JK, Sanda MG, Wei JT, et al. Partners' long-term appraisal of their caregiving experience, marital satisfaction, sexual satisfaction, and quality of life 2 years after prostate cancer treatment. Cancer Nurs 2013; 36:104.
  82. Higano CS. Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer. J Clin Oncol 2012; 30:3720.
  83. Harden J, Northouse L, Cimprich B, et al. The influence of developmental life stage on quality of life in survivors of prostate cancer and their partners. J Cancer Surviv 2008; 2:84.
  84. Committee on Cancer Survivorship: Improving Care and Quality of Life, National Cancer Policy Board. From Cancer Patient to Cancer Survivor: Lost in Transition, Hewitt M, Greenfield S, Stoval E (Eds), Institute of Medicine and National Research Council of the National Academies Press, Washington, DC 2005.
  85. Jacobs LA, Palmer SC, Schwartz LA, et al. Adult cancer survivorship: evolution, research, and planning care. CA Cancer J Clin 2009; 59:391.
  86. Ganz PA. Survivorship: adult cancer survivors. Prim Care 2009; 36:721.
  87. Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010; 76:1245.
  88. Wei JT, Dunn RL, Litwin MS, et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56:899.
  89. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:243.
  90. Chang P, Szymanski KM, Dunn RL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011; 186:865.
  91. http://www.bidmc.org/Centers-and-Departments/Departments/Cancer-Center/ProstateCancerCenter/~/media/Files/CentersandDepartments/CancerCenter/prostateCancer/EPIC%20CP.ashx (Accessed on January 14, 2015).
  92. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res 2005; 17:307.
  93. Litwin MS, Hays RD, Fink A, et al. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998; 36:1002.
  94. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23:7005.
  95. Loeb S, Feng Z, Ross A, et al. Can we stop prostate specific antigen testing 10 years after radical prostatectomy? J Urol 2011; 186:500.
  96. Abramowitz MC, Li T, Buyyounouski MK, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 2008; 112:55.
  97. Cher ML, Bianco FJ Jr, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160:1387.
  98. Choueiri TK, Dreicer R, Paciorek A, et al. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol 2008; 179:906.
  99. Skolarus TA, Holmes-Rovner M, Northouse LL, et al. Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol 2013; 31:727.
  100. Cheung WY, Neville BA, Cameron DB, et al. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 2009; 27:2489.
  101. Bober SL, Recklitis CJ, Campbell EG, et al. Caring for cancer survivors: a survey of primary care physicians. Cancer 2009; 115:4409.
  102. Ercolano E. Follow up of men post-prostatectomy: who is responsible? Urol Nurs 2008; 28:370.
  103. Skolarus TA, Zhang Y, Hollenbeck BK. Understanding fragmentation of prostate cancer survivorship care: implications for cost and quality. Cancer 2012; 118:2837.
  104. Nekhlyudov L, Schnipper JL. Cancer survivorship care plans: what can be learned from hospital discharge summaries? J Oncol Pract 2012; 8:24.
  105. Skolarus TA, Miller DC, Zhang Y, et al. The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol 2010; 184:2279.
  106. Snyder CF, Frick KD, Herbert RJ, et al. Preventive care in prostate cancer patients: following diagnosis and for five-year survivors. J Cancer Surviv 2011; 5:283.